Takeda Pharmaceutical and Enterome Bioscience have entered a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets, which would play crucial roles treating in gastrointestinal disorders.

Under the deal, Enterome will use its metagenomic platform to support the discovery of potential new small molecules or biologics agents from gut bacteria and directed to the GI targets selected by the companies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Takeda will have an option to licence selected agents on an exclusive global basis and will be responsible for their regulatory and clinical development, as well as commercialisation.

"This strategic collaboration represents an important step towards unlocking the microbiome to generate new therapeutic solutions to serious diseases."

Enterome CEO Pierre Belichard said: "This strategic collaboration with Takeda is a significant achievement for Enterome and represents an important step towards realising the full potential of our expertise and unique capabilities in unlocking the microbiome to generate new therapeutic solutions to serious diseases.

"We are delighted to begin this new collaboration, which will combine our continuing leadership in the microbiome space and Takeda’s global therapeutic drug discovery and development capabilities.

See Also:

"It is also an important step for Enterome towards achieving its ambition to become a leading global biopharmaceutical company in the microbiome space."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal will see Enterome receive an upfront payment and three-year R&D funding, and is eligible to receive additional payments in the form of option exercise, development, regulatory and commercial milestone payments for each molecule discovered through the collaboration.

In addition, Enterome is eligible to receive potential tiered royalties on the net sales of any products that are commercialised by Takeda.